Reported about 9 hours ago
Moderna, Inc. is broadening its mRNA therapeutic and vaccine pipeline beyond COVID-19, incorporating treatments for influenza, RSV, and cancer, while facing market challenges due to concerns over vaccine safety. Despite recent stock declines and regulatory scrutiny linked to unverified claims of vaccine-related deaths, the company maintains a focus on transparency and safety, bolstered by extensive real-world data. Leveraging AI in its research and development, Moderna aims to enhance its position in the biotech sector amidst evolving healthcare needs.
Source: YAHOO